PRIME MEMBER EXCLUSIVE | 3 Months Free Trial
Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
#60. Cracking the "Undruggable" Target
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
#60. Cracking the "Undruggable" Target
-
Narrated by:
-
Written by:
Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has been notoriously lethal, with few treatment options. Enter daraxonrasib (RMC-6236), a revolutionary "molecular glue" that targets the active "ON" state of mutated RAS proteins. In the recent Phase 3 RASolute 302 trial, this targeted therapy nearly doubled overall survival for metastatic pancreatic cancer patients compared to standard chemotherapy, extending it to 13.2 months. Join us as we explore the structural biology behind this tri-complex inhibitor, its unique resistance profile, and the future of precision cancer therapy. Produced by Dr. Jake Chen.